Suppr超能文献

干预措施以减轻心血管钙化进展:随机临床试验的系统评价。

Interventions to Attenuate Cardiovascular Calcification Progression: A Systematic Review of Randomized Clinical Trials.

机构信息

Department of Nephrology The Royal Melbourne Hospital Parkville Victoria Australia.

Department of Medicine (RMH) University of Melbourne Parkville Victoria Australia.

出版信息

J Am Heart Assoc. 2023 Dec 5;12(23):e031676. doi: 10.1161/JAHA.123.031676. Epub 2023 Nov 28.

Abstract

BACKGROUND

Cardiovascular calcification, characterized by deposition of calcium phosphate in the arterial wall and heart valves, is associated with cardiovascular morbidity and mortality and is commonly seen in aging, diabetes, and chronic kidney disease. Whether evidence-based interventions could significantly attenuate cardiovascular calcification progression remains uncertain.

METHODS AND RESULTS

We conducted a systematic review of randomized controlled trials involving interventions, compared with placebo, another comparator, or standard of care, to attenuate cardiovascular calcification. Included clinical trials involved participants without chronic kidney disease, and the outcome was cardiovascular calcification measured using radiological methods. Quality of evidence was determined by the Cochrane risk of bias and Grading of Recommendations, Assessment, Development, and Evaluations assessment. Forty-nine randomized controlled trials involving 9901 participants (median participants 104, median duration 12 months) were eligible for inclusion. Trials involving aged garlic extract (n=6 studies) consistently showed attenuation of cardiovascular calcification. Trials involving 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (n=14), other lipid-lowering agents (n=2), hormone replacement therapies (n=3), vitamin K (n=5), lifestyle measures (n=4), and omega-3 fatty acids (n=2) consistently showed no attenuation of cardiovascular calcification with these therapies. Trials involving antiresorptive (n=2), antihypertensive (n=2), antithrombotic (n=4), and hypoglycemic agents (n=3) showed mixed results. Singleton studies involving salsalate, folate with vitamin B6 and 12, and dalcetrapib showed no attenuation of cardiovascular calcification. Overall, Cochrane risk of bias was moderate, and the Grading of Recommendations, Assessment, Development, and Evaluations assessment for a majority of analyses was moderate certainty of evidence.

CONCLUSIONS

Currently, there are insufficient or conflicting data for interventions evaluated in clinical trials for mitigation of cardiovascular calcification. Therapy involving aged garlic extract appears most promising, but evaluable studies were small and of short duration.

摘要

背景

心血管钙化的特征是钙磷酸盐在动脉壁和心脏瓣膜中的沉积,与心血管发病率和死亡率相关,常见于衰老、糖尿病和慢性肾脏病。基于证据的干预措施是否能显著减缓心血管钙化进展仍不确定。

方法

我们对涉及干预的随机对照试验进行了系统回顾,这些干预措施与安慰剂、另一种比较剂或标准护理进行比较,以减缓心血管钙化。纳入的临床试验涉及没有慢性肾脏病的参与者,其结果是使用放射学方法测量的心血管钙化。证据质量由 Cochrane 偏倚风险和推荐评估、制定与评价评估确定。有 49 项随机对照试验涉及 9901 名参与者(中位数参与者 104 岁,中位数持续时间 12 个月)符合纳入标准。涉及 aged garlic extract(n=6 项研究)的试验一致显示出心血管钙化的减缓。涉及 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors(n=14)、其他降脂药物(n=2)、激素替代疗法(n=3)、维生素 K(n=5)、生活方式措施(n=4)和 omega-3 脂肪酸(n=2)的试验一致显示这些疗法对心血管钙化没有减缓作用。涉及抗吸收剂(n=2)、抗高血压药物(n=2)、抗血栓形成药物(n=4)和降血糖药物(n=3)的试验结果不一。涉及 salsalate、叶酸与维生素 B6 和 12、以及 dalcetrapib 的单一研究显示对心血管钙化没有减缓作用。总体而言,Cochrane 偏倚风险为中度,大多数分析的推荐评估、制定与评价评估为中度确定性证据。

结论

目前,临床试验中评估的干预措施减轻心血管钙化的证据不足或相互矛盾。涉及 aged garlic extract 的治疗方法似乎最有希望,但可评估的研究规模较小且持续时间较短。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b39f/10727339/d204598739e7/JAH3-12-e031676-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验